Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism

Area of Science:

• Oncology
• Immunology
• Structural Biology

Background:

• Distinct anti-ErbB2 antibodies exhibit varied biological functions.
• The A21 antibody, developed using surface epitope masking (SEM), is a tumor-inhibitory anti-ErbB2 monoclonal antibody.
• Engineered chA21 antibody shows therapeutic potential for ErbB2-overexpressing tumors.

Purpose of the Study:

• To map the A21 epitope on the ErbB2 extracellular domain (ECD).
• To determine the X-ray crystal structure of the A21 single-chain variable fragment (scFv).
• To investigate the biological functions of A21 and its derivatives on ErbB2-positive cancer cells.

Main Methods:

• Combinatorial phage display peptide library screening.
• Serial subdomain deletion and mutagenesis scanning of ErbB2 ECD.
• X-ray crystallography of A21 scFv and molecular modeling of the antigen-antibody complex.

Main Results:

• A21 recognizes a conformational epitope primarily on ErbB2 extracellular subdomain I.
• Key surface-exposed residues within subdomain I are crucial for A21 binding affinity.
• A21 demonstrates distinct biological functions compared to Herceptin and 2C4, including effects on ErbB2 expression, internalization, and phosphorylation.

Conclusions:

• The A21 epitope represents a novel target for anti-ErbB2 therapeutic development.
• The unique binding and functional properties of A21 offer new strategies for targeting ErbB2-overexpressing cancers.
• Further research into the A21 epitope could lead to next-generation ErbB2-targeted therapies.